These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
261 related items for PubMed ID: 25829091
1. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. Ciarallo A, Marcus C, Taghipour M, Subramaniam RM. PET Clin; 2015 Apr; 10(2):265-78. PubMed ID: 25829091 [Abstract] [Full Text] [Related]
2. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS. PLoS One; 2014 Apr; 9(12):e115127. PubMed ID: 25517451 [Abstract] [Full Text] [Related]
4. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A, Kalinyak JE, McDougall IR. Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020 [Abstract] [Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival. Marcus C, Antoniou A, Rahmim A, Ladenson P, Subramaniam RM. J Med Imaging Radiat Oncol; 2015 Jun; 59(3):281-8. PubMed ID: 25676871 [Abstract] [Full Text] [Related]
6. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan. Chatziioannou SN, Georgakopoulos AT, Pianou NK, Kafiri GT, Pavlou SN, Kallergi M. Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265 [Abstract] [Full Text] [Related]
7. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer. Jiang J, Yang Z, Zhang Y, Xu X, Wang M, Hu S, Yao Z, Pan H, Zhang Y, Li D. Clin Imaging; 2014 Jan; 38(6):797-801. PubMed ID: 24973077 [Abstract] [Full Text] [Related]
8. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. Schreinemakers JM, Vriens MR, Munoz-Perez N, Guerrero MA, Suh I, Rinkes IH, Gosnell J, Shen WT, Clark OH, Duh QY. World J Surg Oncol; 2012 Sep 17; 10():192. PubMed ID: 22985118 [Abstract] [Full Text] [Related]
9. Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging. Abraham T, Schöder H. Semin Nucl Med; 2011 Mar 17; 41(2):121-38. PubMed ID: 21272686 [Abstract] [Full Text] [Related]
10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. BJU Int; 2013 Oct 17; 112(6):729-34. PubMed ID: 23790129 [Abstract] [Full Text] [Related]
11. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. Kwee RM, Marcus C, Sheikhbahaei S, Subramaniam RM. PET Clin; 2015 Apr 17; 10(2):197-205. PubMed ID: 25829086 [Abstract] [Full Text] [Related]
12. PET/CT imaging of thyroid cancer. Mosci C, Iagaru A. Clin Nucl Med; 2011 Dec 17; 36(12):e180-5. PubMed ID: 22064103 [Abstract] [Full Text] [Related]
13. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Kim SJ, Lee TH, Kim IJ, Kim YK. Eur J Radiol; 2009 Apr 17; 70(1):17-24. PubMed ID: 18207685 [Abstract] [Full Text] [Related]
14. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels]. Mariscal Labrador E, García Burillo A, Castell-Conesa J, Obiols Alfonso G, Kisiel González N, Barios Profitós M, Aguadé-Bruix S, Mesa Manteca J. Rev Esp Med Nucl Imagen Mol; 2013 Apr 17; 32(3):146-51. PubMed ID: 22726673 [Abstract] [Full Text] [Related]
15. PET/Computed Tomography and Patient Outcomes in Melanoma. Rohren EM. PET Clin; 2015 Apr 17; 10(2):243-54. PubMed ID: 25829089 [Abstract] [Full Text] [Related]
16. F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer. Iagaru A, McDougall IR. Clin Nucl Med; 2007 Jan 17; 32(1):13-5. PubMed ID: 17179796 [Abstract] [Full Text] [Related]
17. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M. Q J Nucl Med Mol Imaging; 2008 Mar 17; 52(1):2-8. PubMed ID: 17538522 [Abstract] [Full Text] [Related]
19. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Hall NC, Kloos RT. Arq Bras Endocrinol Metabol; 2007 Jul 01; 51(5):793-805. PubMed ID: 17891243 [Abstract] [Full Text] [Related]
20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT. Ann Surg; 2009 Dec 01; 250(6):957-63. PubMed ID: 19687736 [Abstract] [Full Text] [Related] Page: [Next] [New Search]